Prasinezumab slows motor progression, misses main trial goal
Treatment with investigational antibody therapy prasinezumab tended to slow the progression of motor symptoms in people with early-stage Parkinson’s disease in a Phase 2b trial, with particularly pronounced benefits among those also receiving levodopa. However,